Premium
P1–358: Florbetapir PET, FDG‐PET and MRI in people with Down syndrome with and without symptomatic Alzheimer's disease
Author(s) -
Sabbagh Marwan,
Chen Kewei,
Rogers Jospeh,
Liebsack Carolyn,
Bandy Dan,
Belden Christine,
Fleischer Adam,
Thiyyagura Pradeep,
Liu Xioafen,
Parks Stephanie,
Jacobson Sandra,
MalekAhmadi Michael,
Reiman Eric
Publication year - 2013
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.05.585
Subject(s) - voxel , standardized uptake value , nuclear medicine , neuroimaging , medicine , alzheimer's disease , dementia , psychology , pathology , positron emission tomography , disease , neuroscience , radiology
P1-358 FLORBETAPIR PET, FDG-PETAND MRI IN PEOPLE WITH DOWN SYNDROME WITH AND WITHOUT SYMPTOMATIC ALZHEIMER’S DISEASE Marwan Sabbagh, Kewei Chen, Jospeh Rogers, Carolyn Liebsack, Dan Bandy, Christine Belden, Adam Fleischer, Pradeep Thiyyagura, Xioafen Liu, Stephanie Parks, Sandra Jacobson, Michael MalekAhmadi, Eric Reiman, Banner Sun Health Research Institute, Sun City, Arizona, United States; Banner Alzheimer’s Institute, Phoenix, Arizona, United States; Banner Sun Health Research Institute, Sun City, Arizona, United States; Banner Research Institute, Sun City, Arizona, United States. Contact e-mail: marwan.sabbagh@bannerhealth.com